Inclusion Criteria

          -  Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or
             adenosquamous histology, and:

          -  Has experienced disease progression during or after treatment with a standard of care
             systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as
             either:

               -  paclitaxel+cisplatin+bevacizumab, or

               -  paclitaxel+carboplatin+bevacizumab, or

               -  paclitaxel+topotecan/nogitecan+bevacizumab

          -  Note: In cases where bevacizumab is not a standard of care therapy or the participant
             is ineligible for bevacizumab treatment according to local standards, prior treatment
             with bevacizumab is not required.

          -  Has received 1 or 2 prior systemic therapy regimens for recurrent and/or metastatic
             cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or
             in combination with radiation therapy, should not be counted as a systemic therapy
             regimen. Single agent therapy with pembrolizumab for r/mCC cancer should be counted.

          -  Measurable disease according to RECIST v1.1 as assessed by the investigator.

          -  Has ECOG performance status of 0 or 1 prior to randomization.

          -  Has life expectancy of at least 3 months.

        Exclusion Criteria

          -  Has primary neuroendocrine, lymphoid, sarcomatoid, or other histologies not mentioned
             as part of the inclusion criteria above.

          -  Has clinically significant bleeding issues or risks. This includes known past or
             current coagulation defects leading to an increased risk of bleeding; diffuse alveolar
             hemorrhage from vasculitis; known bleeding diathesis; ongoing major bleeding; trauma
             with increased risk of life-threatening bleeding or history of severe head trauma or
             intracranial surgery within 8 weeks of trial entry.

          -  Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, or
             stroke (transient ischemic attack >1 month prior to screening is allowed).

          -  Active ocular surface disease or a history of cicatricial conjunctivitis or
             inflammatory conditions that predispose to cicatrizing conjunctivitis (e.g. Wagner
             syndrome, atopic keratoconjunctivitis, autoimmune disease affecting the eyes), ocular
             Stevens-Johnson syndrome or toxic epidermal necrolysis, mucus pemphigoid, and
             participants with penetrating ocular transplants. Cataracts alone is not an exclusion
             criterion.

          -  Major surgery within 4 weeks or minor surgery within 7 days prior to the first study
             treatment administration.

          -  Peripheral neuropathy ≥grade 2.

          -  Any prior treatment with monomethyl auristatin E (MMAE)-containing drugs.

        There are additional inclusion and exclusion criteria. The study center will determine if
        criteria for participation are met.